Asia
WuXi Biologics, a Shanghai, China-based contract research organization focused on biologics, announced it was expanding its existing collaboration and licensing deals with UK-based Oxford BioTherapeutics (OBT).
New biologics facility, scheduled to be operational in 2020, will provide development and manufacturing facilities from early- to late-clinical and early-commercial stages
It apparently began with a 2016 federal lawsuit. At that time, 20 state attorneys general filed a federal lawsuit alleging that six generic drug makers artificially inflated and manipulated prices for an antibiotic and an oral diabetes drug. The goal was to reduce competition.
Biotech and pharma companies strengthen their leadership teams with these appointments. Who made power moves in the industry this past week?
ADNEC and Abu Dhabi Convention Bureau collaborate to attract key conferences to the capital
he Ministry of Health and Prevention recently met with a Chinese delegation to discuss mutually beneficial cooperation in the use of technological innovations such as artificial intelligence (AI) in the health care sector.
Following the recent claims by He Jiankui, a scientist and professor of Biology at the Southern University of Science and Technology in Shenzhen, Guangdong, China, that he has successfully created the world’s first gene-edited babies,
Todos Medical Ltd. announced that it has entered into a Joint Venture Agreement (JV Agreement) with biotechnology holding company Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) to develop LymPro Test® as a diagnostic blood test for Alzheimer’s disease.
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
Although it was probably not in serious peril, shareholders of Japan’s Takeda Pharmaceutical voted to approve the acquisition of Dublin’s Shire. The deal is currently valued at $58 billion.
PRESS RELEASES